Related Experiment Video
Updated: Jun 24, 2026
Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer
Jian Yu1, Susan Kane, Jiong Wu
1Cell Signaling Technology, Inc., Danvers, Massachusetts, USA.
Purpose:
Activating mutations within the tyrosine kinase domain of epidermal growth factor receptor (EGFR) are found in approximately 10% to 20% of non-small-cell lung cancer (NSCLC) patients and are associated with response to EGFR inhibitors. The most common NSCLC-associated EGFR mutations are deletions in exon 19 and L858R mutation in exon 21, together accounting for 90% of EGFR mutations. To develop a simple, sensitive, and reliable clinical assay for the identification of EGFR mutations in NSCLC patients, we generated mutation-specific rabbit monoclonal antibodies against each of these two most common EGFR mutations and aimed to evaluate the detection of EGFR mutations in NSCLC patients by immunohistochemistry.
Experimental Design:
We tested mutation-specific antibodies by Western blot, immunofluorescence, and immunohistochemistry. In addition, we stained 40 EGFR genotyped NSCLC tumor samples by immunohistochemistry with these antibodies. Finally, with a panel of four antibodies, we screened a large set of NSCLC patient samples with unknown genotype and confirmed the immunohistochemistry results by DNA sequencing.
Results:
These two antibodies specifically detect the corresponding mutant form of EGFR by Western blotting, immunofluorescence, and immunohistochemistry. Screening a panel of 340 paraffin-embedded NSCLC tumor samples with these antibodies showed that the sensitivity of the immunohistochemistry assay is 92%, with a specificity of 99% as compared with direct and mass spectrometry-based DNA sequencing.
Conclusions:
This simple assay for detection of EGFR mutations in diagnostic human tissues provides a rapid, sensitive, specific, and cost-effective method to identify lung cancer patients responsive to EGFR-based therapies.
Insights
This study developed specific antibodies to detect common epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer (NSCLC). The new immunohistochemistry assay is a rapid, sensitive, and specific method for identifying patients who can benefit from targeted therapies.
Area of Science:
- Oncology
- Molecular Biology
- Immunohistochemistry
Background:
- Activating mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase domain are present in 10-20% of non-small-cell lung cancer (NSCLC) patients.
- The most prevalent EGFR mutations in NSCLC are exon 19 deletions and the L858R mutation in exon 21, collectively representing 90% of all EGFR mutations.
- These mutations are critical biomarkers for predicting response to EGFR inhibitor therapies.
Purpose of the Study:
- To develop a simple, sensitive, and reliable clinical assay for identifying common EGFR mutations in NSCLC.
- To generate mutation-specific rabbit monoclonal antibodies targeting the two most frequent EGFR mutations (exon 19 deletions and L858R).
- To evaluate the efficacy of these antibodies for detecting EGFR mutations in NSCLC patient samples using immunohistochemistry.
Main Methods:
- Mutation-specific antibodies were validated using Western blot, immunofluorescence, and immunohistochemistry.
- Forty EGFR-genotyped NSCLC tumor samples were stained via immunohistochemistry.
- A panel of four antibodies was used to screen a large set of NSCLC samples with unknown genotypes, with results confirmed by DNA sequencing.
Main Results:
- The generated antibodies demonstrated specific detection of their corresponding mutant EGFR forms across multiple assay types.
- Immunohistochemical screening of 340 paraffin-embedded NSCLC tumor samples revealed an assay sensitivity of 92% and a specificity of 99% compared to DNA sequencing.
- The assay accurately identified EGFR mutations in NSCLC tissues.
Conclusions:
- A novel immunohistochemistry assay utilizing mutation-specific antibodies offers a rapid, sensitive, and specific method for EGFR mutation detection.
- This assay is a cost-effective tool for identifying NSCLC patients eligible for EGFR-targeted therapies.
- The developed assay facilitates personalized medicine approaches in lung cancer treatment.
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...